Comparison of the effectiveness of intramuscular olanzapine with intramuscular haloperidol for the treatment of agitation in patients with Bipolar Disorder, A randomized controlled study.

niversity of social welfare and rehabilitation sciences0 个研究点目标入组 40 人开始时间: 待定最近更新: 2024年3月6日

适应症

试验速览

暂无简介。

•Patients with Bipolar Disorder diagnosed based on DSM-5 criteria according to clinical interview of psychiatrist.
•Having an overall score of 14 and above (up to 35) in PANSS including five cases of tension, uncooperativeness, hostility, poor impulse control and excitement.
•Having a rating of 4 (max 7) in at least one of the above five
•The psychiatrist concludes that the patient should be treated with Olanzapine IM injection or Haloperidol
•No physical illness associated with mental retardation or other cognitive disorders and neurological disorders
•Not having severe cardiovascular diseases or cerberovascular in the past 6 months, any severe, acute or unstable medical conditions or laboratory disorders and uncontrolled underlying disease
•No NMS history
•No dependence or abuse of substances, drugs or alcohol acutely or in the past 12 months except nicotine or positive urine screen test
•Patient or guardian's consent

•Patients with a history of allergic reaction or intolerance to Olanzapine or Haloperidol.
•Patients with psychomotor restlessness who have not been diagnosed with bipolar disorder.
•Unwillingness of the patient or the patient's family to participate in the study.
•Pregnant or nursing women
•Patients who have received antipsychotics depo-injectable drugs during the last 1 month.
•Patients who have used psychological stimuli within 1 week.
•Patients who received oral or injectable benzodiazepines within the last 4 hours.
•Patients who have received oral or rapid muscular antipsychotics in the last 2 hours.

发起方

niversity of social welfare and rehabilitation sciences